Cargando…
Cellular response to alkylating agent MNNG is impaired in STAT1‐deficients cells
The S(N)1 alkylating agents activate the mismatch repair system leading to delayed G(2)/M cell cycle arrest and DNA repair with subsequent survival or cell death. STAT1, an anti‐proliferative and pro‐apoptotic transcription factor is known to potentiate p53 and to affect DNA‐damage cellular response...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020624/ https://www.ncbi.nlm.nih.gov/pubmed/27464833 http://dx.doi.org/10.1111/jcmm.12887 |
Sumario: | The S(N)1 alkylating agents activate the mismatch repair system leading to delayed G(2)/M cell cycle arrest and DNA repair with subsequent survival or cell death. STAT1, an anti‐proliferative and pro‐apoptotic transcription factor is known to potentiate p53 and to affect DNA‐damage cellular response. We studied whether STAT1 may modulate cell fate following activation of the mismatch repair system upon exposure to the alkylating agent N‐methyl‐N′‐nitro‐N‐nitrosoguanidine (MNNG). Using STAT1‐proficient or ‐deficient cell lines, we found that STAT1 is required for: (i) reduction in the extent of DNA lesions, (ii) rapid phosphorylation of T68‐CHK2 and of S15‐p53, (iii) progression through the G(2)/M checkpoint and (iv) long‐term survival following treatment with MNNG. Presence of STAT1 is critical for the formation of a p53‐DNA complex comprising: STAT1, c‐Abl and MLH1 following exposure to MNNG. Importantly, presence of STAT1 allows recruitment of c‐Abl to p53‐DNA complex and links c‐Abl tyrosine kinase activity to MNNG‐toxicity. Thus, our data highlight the important modulatory role of STAT1 in the signalling pathway activated by the mismatch repair system. This ability of STAT1 to favour resistance to MNNG indicates the targeting of STAT1 pathway as a therapeutic option for enhancing the efficacy of SN1 alkylating agent‐based chemotherapy. |
---|